Press Releases
- Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod October 3, 2012 18:30 (CEST)
- Tasquinimod Biomarker Phase II data presented at ESMO 2012 October 1, 2012 08:30 (CEST)
- Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference September 6, 2012 08:30 (CEST)
- Active Biotech AB Interim report January - June 2012 August 10, 2012 08:30 (CEST)
- TEVA TO INITIATE THIRD PHASE III TRIAL OF ORAL LAQUINIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS August 8, 2012 14:00 (CEST)
- ACTIVE BIOTECH ANNOUNCE THAT EUROPEAN MEDICINES AGENCY ACCEPTS START OF SCIENTIFIC REVIEW OF THE MARKETING AUTHORIZATION APPLICATION FOR LAQUINIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS July 17, 2012 08:30 (CEST)
- Active Biotech's and Ipsen's Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer June 4, 2012 15:00 (CEST)
- Active Biotech to Present at the Jefferies 2012 Global Healthcare Conference May 31, 2012 08:30 (CEST)
- Active Biotech invites to Capital Markets Day May 29, 2012 13:00 (CEST)
- 600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study May 21, 2012 07:30 (CEST)